Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 7.23% in last session and finished the day at $ … Continue reading Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in the last session and the average volume of the stock … Continue reading Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock … Continue reading Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)